Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery

Nanomedicine

Volumn 5, Issue 2, 2010, Pages 287-306

  Roger, Emilie ^b,c   Lagarce, Frederic ^a,c   Garcion, Emmanuel ^c   Benoit, Jean Pierre ^a,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Ethypharm   (France)

^c INSERM   (France)

Author keywords

Bioavailability; Biopharmaceutics; Gastrointestinal tract; Nanocarrier; Oral absorption; Oral administration

Indexed keywords

CEFOTAXIME; CEFUROXIME AXETIL; CHITOSAN; CLOZAPINE; CYCLOSPORIN A; DENDRIMER; DOXORUBICIN; FENOFIBRATE; GENISTEIN; INSULIN; LIGAND; LIPID NANOCAPSULE; LIPOSOME; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOPARTICLE; NANOSPHERE; NITRENDIPINE; PACLITAXEL; POLYAMIDOAMINE; POLYGLACTIN; POLYMER; POLYSTYRENE; QUERCETIN; SALCATONIN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCAMINE; VINPOCETINE;

BIOAVAILABILITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; GASTROINTESTINAL TRACT; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PATIENT COMPLIANCE; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURFACE PROPERTY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DIFFUSION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; INTESTINES; LIGANDS; MUCUS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 77952491719     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.110     Document Type: Review

References (198)

1. Koo OM, Rubinstein I, Onyuksel H: Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed. 1, 193-212 (2005).
2. Manjunathand K, Venkateswarlu V: Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control Release 107, 215-228 (2005).
3. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H: Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control Release 133, 238-244 (2009).
4. Kumar V V, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV: Development and evaluation of nitrendipine loaded solid lipid nanoparticles: infuence of wax and glyceride lipids on plasma pharmacokinetics. Int. J. Pharm. 335, 167-175 (2007).
5. Luo Y, Chen D, Ren L, Zhao X, Qin J: Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control Release 114, 53-59 (2006).
6. Maincent P, Le Verge R, Sado P, Couvreur P, Devissaguet JP: Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J. Pharm. Sci. 75, 955-958 (1986).
7. El-Shabouri MH: Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 249, 101-108 (2002).
8. Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP: Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23, 1243-1250 (2006).
9. Cui F, Shi K, Zhang L, Tao A, Kawashima Y: Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control Release 114, 242-250 (2006).
10. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW: In vivo evaluation of safety and effcacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30, 2329-2339 (2009).
11. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN: Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm. Res. 26, 492-501 (2009).
12. Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P: Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur. J. Pharm. Biopharm. 70, 109-115 (2008).
13. Li H, Song JH, Park JS, Han K: Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int. J. Pharm. 258, 11-19 (2003).
14. Sun W, Zou W, Huang G, Li A, Zhang N: Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J. Drug Target. 16, 357-365 (2008).
15. Ling SS, Magosso E, Khan NA, Yuen KH, Barker SA: Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev. Ind. Pharm. 32, 335-345 (2006).
16. Anderson KE, Eliot LA, Stevenson BR, Rogers JA: Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm. Res. 18, 316-322 (2001).
17. Yamabe K, Kato Y, Onishi H, Machida Y: Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J. Control Release 89, 429-436 (2003). (Pubitemid 36555902)
18. Kwon SH, Kim SY, Ha KW et al.: Pharmaceutical evaluation of genistein-loaded pluronic micelles for oral delivery. Arch Pharm. Res. 30, 1138-1143 (2007).
19. Sant V P, Smith D, Leroux JC: Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. J. Control Release 104, 289-300 (2005).
20. Ke W, Zhao Y, Huang R, Jiang C, Pei Y: Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J. Pharm. Sci. 97, 2208-2216 (2008).
21. Hussain N, Florence AT: Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm. Res. 15, 153-156 (1998).
22. Jani P, Halbert GW, Langridge J, Florence AT: Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42, 821-826 (1990).
23. Francis MF, Cristea M, Winnik FM: Polymeric micelles for oral drug delivery: why and how. Pure Appl. Chem. 76, 1321-1335 (2004).
24. Hillery AM, Lloyd AW, Swarbrick J: Drug Delivery and Targeting for Pharmacist and Pharmaceutical Scientists. Taylor & Francis, NY, USA (2001).
25. Dressman LHJ: Oral Drug Absorption: Prediction and Assessment. Marcel Decker, Inc., NY, USA (2000).
26. Dressman JB, Amidon GL, Reppas C, Shah VP: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15, 11-22 (1998).
27. Horterand D, Dressman JB: Infuence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46, 75-87 (2001).
28. Lipkaand E, Amidon GL: Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J. Control Release 62, 41-49 (1999)
29. USP. United States Pharmacopeia 32. Offcial Compendia of Standards. The United States Pharmacopeial Convention, Rockville, MD, USA (2008)
30. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB: Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15, 698-705 (1998).
31. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C: Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm. 60, 413-417 (2005).
32. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C: Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23, 165-176 (2006).
33. Jantratid E, Janssen N, Chokshi H, Tang K, Dressman JB: Designing biorelevant dissolution tests for lipid formulations: case example-lipid suspension of RZ-50. Eur. J. Pharm. Biopharm. 69, 776-785 (2008).
34. Jantratid E, Janssen N, Reppas C, Dressman JB: Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25, 1663-1676 (2008).
35. Vertzoni M, Fotaki N, Kostewicz E et al.: Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56, 453-462 (2004).
36. Kalantzi L, Persson E, Polentarutti B et al.: Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm. Res. 23, 1373-1381 (2006).
37. Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L: A dynamic in vitro lipolysis model. II: evaluation of the model. Eur. J. Pharm. Sci. 14, 237-244 (2001).
38. Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L: A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur. J. Pharm. Sci. 14, 115-122 (2001).
39. Müller RH, Rühl D, Runge SA: Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 144, 115-121 (1996).
40. Olbrichand C, Müller RH: Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 180, 31-39 (1999).
41. Woodley JF: Liposomes for oral administration of drugs. Crit. Rev. Ther. Drug Carrier Syst. 2, 1-18 (1985).
42. Arien A, Goigoux C, Baquey C, Dupuy B: Study of in vitro and in vivo stability of liposomes loaded with calcitonin or indium in the gastrointestinal tract. Life Sci. 53, 1279-1290 (1993).
43. Andrieux K, Forte L, Lesieur S, Paternostre M, Ollivon M, Grabielle-Madelmont C: Solubilisation of dipalmitoyl-phosphatidylcholine bilayers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. Eur. J. Pharm. Biopharm. 71, 346-355 (2009).
44. Rogersand JA, Anderson KE: The potential of liposomes in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 15, 421-480 (1998).
45. Kokkona M, Kallinteri P, Fatouros D, Antimisiaris SG: Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur. J. Pharm. Sci. 9, 245-252 (2000).
46. Maitani Y, Hazama M, Tojo Y, Shimoda N, Nagai T: Oral administration of recombinant human erythropoietin in liposomes in rats: infuence of lipid composition and size of liposomes on bioavailability. J. Pharm. Sci. 85, 440-445 (1996).
47. Rowlandand RN, Woodley JF: Uptake of free and liposome-entrapped horseradish peroxidase by rat intestinal sacs in vitro. FEBS Lett. 123, 41-44 (1981).
48. Rowlandand RN, Woodley JF: The stability of liposomes in vitro to pH, bile salts and pancreatic lipase. Biochim. Biophys. Acta 620, 400-409 (1980).
49. Iwanaga K, Ono S, Narioka K et al.: Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci. 88, 248-252 (1999).
50. Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N: Application of polyethyleneglycol (PEG)-modifed liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J. Control Release 89, 189-197 (2003).
51. Iwanaga K, Ono S, Narioka K et al.: Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int. J. Pharm. 157, 73-80 (1997).
52. Filipovic-Grcic J, Skalko-Basnet N, Jalsenjak I: Mucoadhesive chitosan-coated liposomes: characteristics and stability. J. Microencapsul. 18, 3-12 (2001).
53. Trapani A, Garcia-Fuentes M, Alonso MJ: Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19, 185101 (2008).
54. Pan Y, Li YJ, Zhao HY et al.: Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249, 139-147 (2002).
55. Vauthier C, Labarre D, Ponchel G: Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J. Drug Target. 15, 641-663 (2007).
56. Ramachandran R, Paul W, Sharma CP: Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery. J. Biomed. Mater. Res. Part B Appl. Biomater. 88, 41-48 (2009).
57. Landry FB, Bazile DV, Spenlehauer G, Veillard M, Kreuter J: Degradation of poly(D,L-lactic acid) nanoparticles coated with albumin in model digestive fuids (USP XXII). Biomaterials 17, 715-723 (1996).
58. Tobío M, Sánchez A, Vila A et al.: The role of PEG on the stability in digestive fuids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B Biointerfaces 18, 315-323 (2000).
59. des Rieux A, Fievez V, Momtaz M et al.: Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control Release 118, 294-302 (2007). (Pubitemid 46442879)
60. García-Fuentes M, Torres D, Alonso MJ: Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B Biointerfaces 27, 159-168 (2003).
61. Sahu A, Bora U, Kasoju N, Goswami P: Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 4, 1752-1761 (2008).
62. Kim S, Kim JY, Huh KM, Acharya G, Park K: Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J. Control Release 132(3), 222-229 2008.
63. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP: A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19, 875-880 (2002).
64. Minkov I, Ivanova T, Panaiotov I, Proust J, Saulnier P: Reorganization of lipid nanocapsules at air-water interface: part 2. Properties of the formed surface flm. Colloids Surf. B Biointerfacess 44, 197-203 (2005).
65. Eliyahu H, Joseph A, Schillemans JP, Azzam T, Domb AJ, Barenholz Y: Characterization and in vivo performance of dextran-spermine polyplexes and DOTAP/cholesterol lipoplexes administered locally and systemically. Biomaterials 28, 2339-2349 (2007).
66. Fagerholmand U, Lennernäs H: Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci. 3, 247-253 (1995).
67. Lennernas H: Human intestinal permeability. J. Pharm. Sci. 87, 403-410 (1998).
68. Norris DA, Puri N, Sinko PJ: The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 34, 135-154 (1998).
69. Lai SK, Wang YY, Hanes J: Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158-171 (2009).
70. Behrens I, Pena AI, Alonso MJ, Kissel T: Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19, 1185-1193 (2002).
71. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar M: Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm. Res. 23, 184-195 (2006).
72. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G: Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 28, 2233-2243 (2007). (Pubitemid 46216448)
73. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM: The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30, 2790-2798 (2009).
74. Pietzonka P, Rothen-Rutishauser B, Langguth P, Wunderli-Allenspach H, Walter E, Merkle HP: Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake. Pharm. Res. 19, 595-601 (2002).
75. Gaumet M, Gurny R, Delie F: Localization and quantifcation of biodegradable particles in an intestinal cell model: the infuence of particle size. Eur. J. Pharm. Sci. 36, 465-473 (2009).
76. Zha LY, Xu ZR, Wang MQ, Gu LY: Chromium nanoparticle exhibits higher absorption effciency than chromium picolinate and chromium chloride in Caco-2 cell monolayers. J. Anim. Physiol. Anim. Nutr. (Berl.) 92, 131-140 (2008).
77. Maand Z, Lim LY: Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20, 1812-1819 (2003).
78. Mi FL, Wu YY, Lin YH et al.: Oral delivery of peptide drugs using nanoparticles self-assembled by poly(g-glutamic acid) and a chitosan derivative functionalized by trimethylation. Bioconjug. Chem. 19, 1248-1255 (2008).
79. Lin YH, Mi FL, Chen CT et al.: Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8, 146-152 (2007).
80. Prego C, Garcia M, Torres D, Alonso MJ: Transmucosal macromolecular drug delivery. J. Control Release 101, 151-162 (2005).
81. Lin YH, Sonaje K, Lin KM et al.: Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J. Control Release 132, 141-149 (2008).
82. Sang Yooand H, Gwan Park T: Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J. Pharm. Sci. 93, 488-495 (2004).
83. Fillafer C, Friedl DS, Wirth M, Gabor F: Fluorescent bionanoprobes to characterize cytoadhesion and cytoinvasion. Small 4, 627-633 (2008).
84. Weissenboeck A, Bogner E, Wirth M, Gabor F: Binding and uptake of wheat germ agglutinin-grafted PLGA-nanospheres by Caco-2 monolayers. Pharm. Res. 21, 1917-1923 (2004).
85. Lochner N, Pittner F, Wirth M, Gabor F: Wheat germ agglutinin binds to the epidermal growth factor receptor of artifcial Caco-2 membranes as detected by silver nanoparticle enhanced fuorescence. Pharm. Res. 20, 833-839 (2003).
86. Gao X, Wang T, Wu B et al.: Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. Biochem. Biophys. Res. Commun. 377, 35-40 (2008).
87. Zhangand Z, Feng SS: Self-assembled nanoparticles of poly(lactide)- vitamin E TPGS copolymers for oral chemotherapy. Int. J. Pharm. 324, 191-198 (2006).
88. Koch AM, Reynolds F, Merkle HP, Weissleder R, Josephson L: Transport of surface-modifed nanoparticles through cell monolayers. Chembiochem 6, 337-345 (2005).
89. Chen F, Zhang ZR, Yuan F, Qin X, Wang M, Huang Y: In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int. J. Pharm. 349, 226-233 (2008).
90. Cheng WP, Gray AI, Tetley L, Hang Tle M, Schatzlein AG, Uchegbu IF: Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds. Biomacromolecules 7, 1509-1520 (2006).
91. Roger E, Lagarce F, Garcion E, Benoit JP: Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control Release 140(2), 174-181 (2009).
92. Sattler S, Schaefer U, Schneider W, Hoelzl J, Lehr CM: Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. J. Pharm. Sci. 86, 1120-1126 (1997).
93. Mathot F, des Rieux A, Arien A, Schneider YJ, Brewster M, Preat V: Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. J. Control Release 124, 134-143 (2007).
94. Sezgin Z, Yuksel N, Baykara T: Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm. 332, 161-167 (2007).
95. Batrakova EV, Han HY, Miller DW, Kabanov AV: Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 15, 1525-1532 (1998).
96. Jevprasesphant R, Penny J, Attwood D, McKeown NB, D'Emanuele A: Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 20, 1543-1550 (2003).
97. El-Sayed M, Rhodes CA, Ginski M, Ghandehari H: Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 265, 151-157 (2003).
98. Kitchens KM, Foraker AB, Kolhatkar RB, Swaan PW, Ghandehari H: Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 24, 2138-2145 (2007).
99. Kitchens KM, Kolhatkar RB, Swaan PW, Ghandehari H: Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol. Pharm. 5, 364-369 (2008)
100. des Rieux A, Ragnarsson EG, Gullberg E, Preat V, Schneider YJ, Artursson P: Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25, 455-465 (2005).
101. Nellans HN: (B) Mechanisms of peptide and protein absorption: (1) Paracellular intestinal transport: modulation of absorption. Adv. Drug Deliv. Rev. 7, 339-364 (1991).
102. Volkheimer G: Persorption of particles: physiology and pharmacology. Adv. Pharmacol. Chemother. 14, 163-187 (1977).
103. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T: Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50, 147-160 (2000).
104. Ward PD, Tippin TK, Thakker DR: Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Technol. Today 3, 346-358 (2000).
105. Salamat-Millerand N, Johnston TP: Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294, 201-216 (2005).
106. Sadeghi AM, Dorkoosh FA, Avadi MR et al.: Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70, 270-278 (2008).
107. Arturssonand P, Borchardt RT: Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14, 1655-1658 (1997).
108. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H: Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 10, 195-204 (2000).
109. Washington N, Washington C, Wilson CG: Physiological pharmaceutics: Barriers to drug absorption. Taylor & Francis, NY, USA (2001).
110. Yoncheva K, Gomez S, Campanero MA, Gamazo C, Irache JM: Bioadhesive properties of pegylated nanoparticles. Expert Opin. Drug. Deliv. 2, 205-218 (2005).
111. Mathot F, Schanck A, Van Bambeke F et al.: Passive diffusion of polymeric surfactants across lipid bilayers. J. Control Release 120, 79-87 (2007).
112. Winand KY, Feng SS: Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713-2722 (2005).
113. Gebert A, Rothkotter HJ, Pabst R: M cells in Peyer's patches of the intestine. Int. Rev. Cytol. 167, 91-159 (1996).
114. Yeh P, Ellens H, Smith PL: Physiological considerations in the design of particulate dosage forms for oral vaccine delivery. Adv. Drug Deliv. Rev. 34, 123-133 (1998).
115. Florence AT: Nanoparticle uptake by the oral route: fulflling its potential? Drug Discov. Today: Technologies. 2, 75-81 (2005).
116. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control Release 116, 1-27 (2006).
117. Damge C, Reis CP, Maincent P: Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug. Deliv. 5, 45-68 (2008).
118. Delieand F, Blanco-Prieto MJ: Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10, 65-80 (2005).
119. Brayden DJ, Jepson MA, Baird AW: Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 10, 1145-1157 (2005).
120. Brayden DJ: Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci. 14, 183-189 (2001).
121. Fosterand N, Hirst BH: Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev. 57, 431-450 (2005).
122. Clark MA, Jepson MA, Hirst BH: Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 50, 81-106 (2001).
123. Florence AT: The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14, 259-266 (1997).
124. Kuoleeand R, Chen W: M cell-targeted delivery of vaccines and therapeutics. Expert Opin. Drug. Deliv. 5, 693-702 (2008).
125. Vyasand SP, Gupta PN: Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 6, 401-418 (2007).
126. Jepson MA, Clark MA, Hirst BH: M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv. Drug Deliv. Rev. 56, 511-525 (2004).
127. Lambkinand I, Pinilla C: Targeting approaches to oral drug delivery. Expert Opin. Biol. Ther. 2, 67-73 (2002).
128. Lavelle EC, Sharif S, Thomas NW, Holland J, Davis SS: The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv. Drug Deliv. Rev. 18, 5-22 (1995).
129. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP: M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 15, 701-713 (2007).
130. Garinot M, Fievez V, Pourcelle V et al.: PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control Release 120, 195-204 (2007).
131. Gullberg E, Keita AV, Salim SY et al.: Identifcation of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J. Pharmacol. Exp. Ther. 319, 632-639 (2006).
132. Gullberg E, Leonard M, Karlsson J et al.: Expression of specifc markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279, 808-813 (2000).
133. Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH: Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20, 208-217 (2001).
134. Pinto-Alphandary H, Aboubakar M, Jaillard D, Couvreur P, Vauthier C: Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm. Res. 20, 1071-1084 (2003).
135. Damge C, Aprahamian M, Humbert W, Pinget M: Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol. 52, 1049-1056 (2000).
136. O'Hagan ST: Intestinal translocation of particulates-implications for drug and antigen delivery. Adv. Drug Deliv. Rev. 5, 265-285 (1990).
137. Connerand DS, Schmid SL: Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
138. Snoeck V, Goddeeris B, Cox E: The role of enterocytes in the intestinal barrier function and antigen uptake. Microbes Infect. 7, 997-1004 (2005).
139. Somsel RJ, Wandinger-Ness A: Rab GTPases coordinate endocytosis. J. Cell Sci. 113(Pt 2) 183-192 (2000).
140. Johannesand L, Lamaze C: Clathrin-dependent or not: is it still the question? Traffc 3, 443-451 (2002).
141. Ragnarsson EG, Schoultz I, Gullberg E et al.: Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab. Invest. 88, 1215-1226 (2008).
142. Benmerahand A, Lamaze C: Clathrin-coated pits: vive la difference? Traffc 8, 970-982 (2007).
143. Ehrlich M, Boll W, Van Oijen A et al.: Endocytosis by random initiation and stabilization of clathrin-coated pits. Cell 118, 591-605 (2004).
144. Kitchens KM, El-Sayed ME, Ghandehari H: Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv. Drug Deliv. Rev. 57, 2163-2176 (2005).
145. Nichols B: Caveosomes and endocytosis of lipid rafts. J. Cell Sci. 116, 4707-4714 (2003).
146. Lajoieand P, Nabi IR: Regulation of raft-dependent endocytosis. J. Cell. Mol. Med. 11, 644-653 (2007).
147. Field FJ, Born E, Murthy S, Mathur SN: Caveolin is present in intestinal cells: role in cholesterol traffcking? J. Lipid Res. 39, 1938-1950 (1998).
148. Montesano R, Roth J, Robert A, Orci L: Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 296, 651-653 (1982).
149. Simonsand K, Ikonen E: Functional rafts in cell membranes. Nature 387, 569-572 (1997).
150. Pelkmans L, Kartenbeck J, Helenius A: Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3, 473-483 (2001).
151. Medina-Kauwe LK: "Alternative" endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery? Adv. Drug Deliv. Rev. 59, 798-809 (2007).
152. Schnitzer JE, Oh P, Pinney E, Allard J: Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell Biol. 127, 1217-1232 (1994).
153. Trevaskis NL, Charman WN, Porter CJ: Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 60, 702-716 (2008).
154. Panyamand J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329-347 (2003).
155. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V: Rapid endolysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J. 16, 1217-1226 (2002).
156. Panyamand J, Labhasetwar V: Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 20, 212-220 (2003).
157. Park JS, Han TH, Lee KY et al.: N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J. Control Release 115, 37-45 (2006).
158. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP: Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29, 3477-3496 (2008).
159. Anderson RG, Kamen BA, Rothberg KG, Lacey SW: Potocytosis: sequestration and transport of small molecules by caveolae. Science 255, 410-411 (1992).
160. Swaan PW: Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm. Res. 15, 826-834 (1998).
161. Kesisoglou F, Panmai S, Wu Y: Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644 (2007).
162. Hecq J, Deleers M, Fanara D et al.: Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-35443, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 64, 360-368 (2006).
163. Jia L, Wong H, Cerna C, Weitman SD: Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm. Res. 19, 1091-1096 (2002).
164. Gao H, Shi W, Freund LB: Mechanics of receptor-mediated endocytosis. Proc. Natl Acad. Sci. USA 102, 9469-9474 (2005).
165. Singhand R, Lillard JW Jr: Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86, 215-223 (2009).
166. Chithrani BD, Ghazani AA, Chan WC: Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662-668 (2006).
167. Desai MP, Labhasetwar V, Amidon GL, Levy RJ: Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13, 1838-1845 (1996).
168. Rejman J, Oberle V, Zuhorn IS, Hoekstra D: Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. 377, 159-169 (2004).
169. Kawaguchi H: Functional polymer microspheres. Prog. Polym. Sci.25, 1171-1210 (2000).
170. Douglas SJ, Davis SS, Illum L: Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 3, 233-261 (1987).
171. Krauel K, Davies NM, Hook S, Rades T: Using different structure types of microemulsions for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization. J. Control Release 106, 76-87 (2005).
172. Damgé C, Aprahamian M, Balboni G, Hoeltzel A, Andrieu V, Devissaguet JP: Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int. J. Pharm. 36, 121-125 (1987).
173. Wissing SA, Kayser O, Muller RH: Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257-1272 (2004).
174. Heurtault B, Saulnier P, Pech B et al.: The infuence of lipid nanocapsule composition on their size distribution. Eur. J. Pharm. Sci. 18, 55-61 (2003).
175. Suggy SC, Murari R, Imran A: Liposomes (a review)-part one: manufacturing issues. Biopharm. 14, 10 (2001).
176. Roger E, Lagarce F, Benoit JP: The gastrointestinal stability of lipid nanocapsules. Int. J. Pharm. 379, 260-265 (2009).
177. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ: Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 386, 243-246 (1996).
178. Sakuma S, Hayashi M, Akashi M: Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv. Drug Deliv. Rev. 47, 21-37 (2001).
179. Dodou D, Breedveld P, Wieringa PA: Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. Eur. J. Pharm. Biopharm. 60, 1-16 (2005).
180. Takeuchi H, Yamamoto H, Kawashima Y: Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47, 39-54 (2001). (Pubitemid 32209231)
181. Yin Y, Chen D, Qiao M, Wei X, Hu H: Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control Release 123, 27-38 (2007).
182. Singhand MD, O'Hagan: The preparation and characterization of polymeric antigen delivery systems for oral administration. Adv. Drug Deliv. Rev. 34, 285-304 (1998).
183. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y: Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353, 26-32 (2007).
184. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL: Studies on oral absorption of stearic acid SLN by a novel fuorometric method. Colloids Surf. B Biointerfacess 58, 157-164 (2007).
185. Mudhakir D, Akita H, Tan E, Harashima H: A novel IRQ ligand-modifed nano-carrier targeted to a unique pathway of caveolar endocytic pathway. J. Control Release 125, 164-173 (2008).
186. Barefordand LM, Swaan PW: Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59, 748-758 (2007).
187. Chithraniand BD, Chan WC: Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7, 1542-1550 (2007).
188. Muro S, Schuchman EH, Muzykantov VR: Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation-and clathrin-dependent endocytosis. Mol. Ther. 13, 135-141 (2006).
189. Poncheland G, Irache J: Specifc and non-specifc bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34, 191-219 (1998).
190. Kilpatrick DC, Pusztai A, Grant G, Graham C, Ewen SW: Tomato lectin resists digestion in the mammalian alimentary canal and binds to intestinal villi without deleterious effects. FEBS Lett. 185, 299-305 (1985).
191. Hussain N, Jani PU, Florence AT: Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res. 14, 613-618 (1997).
192. Florence AT, Hillery AM, Hussain N, Jani PU: Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J. Control Release 36, 39-46 (1995).
193. Gabrielsonand NP, Pack DW: Effcient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells. J. Control Release 136(1), 54-61 (2009).
194. Russell-Jones GJ, Arthur L, Walker H: Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. Int. J. Pharm. 179, 247-255 (1999). (Pubitemid 29131434)
195. Samstein RM, Perica K, Balderrama F, Look M, Fahmy TM: The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials 29, 703-708 (2008).
196. Leroux JC, Cozens R, Roesel JL et al.: Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J. Pharm. Sci. 84, 1387-1391 (1995).
197. Amidon GL, Lennernas H, Shah V P, Crison JR: A theoretical basis for a biopharmaceutic drug classifcation: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995).
198. Tumaand PL, Hubbard AL: Transcytosis: crossing cellular barriers. Physiol. Rev. 83, 871-932 (2003).